Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

EpimAb Biotherapeutics

Request full access

Developing a portfolio of novel bi-specific antibodies in oncology and immune-oncology

Pudong, ChinaFounded 2015Biotech & Life Sciences

About EpimAb Biotherapeutics

EpimAb is a biopharmaceutical startup that operates in the oncology sector, developing innovative cancer treatments. The company has a robust and sustainable product pipeline, with four clinical projects and over ten pre-clinical candidate drugs. EpimAb's proprietary FIT-Ig® platform allows the company to precisely target three strategic oncology areas: tumor targeting, dual immune checkpoint, and immune cell guidance. This means they develop drugs that can target specific cancer cells, check the immune system's response, and guide immune cells to the tumor.

One of their key products, EMB-01, is a novel bispecific antibody, a type of drug that can bind to two different proteins at the same time. EMB-01 targets EGFR and cMet on tumor cells, which are proteins that can promote cancer growth. This drug is currently in Phase I/II clinical trials for non-small cell lung cancer (NSCLC) and several gastrointestinal (GI) cancers in the U.S. and China.

Another product, EMB-06, is a recombinant humanized bispecific antibody that targets B cell maturation antigen (BCMA) and cluster of differentiation 3 (CD3) on tumor cells. This drug can recruit and activate T lymphocytes, a type of white blood cell, to kill tumor cells. It is currently in a global Phase I/II study in Australia and China for multiple myeloma, a type of blood cancer.

EpimAb's business model revolves around the research, development, and commercialization of these innovative cancer treatments. The company makes money by progressing these drugs through clinical trials and eventually selling them to healthcare providers and patients.

Source: Dealroom company data

At a glance

Status
Operational
Employees
37
Open positions
None listed
Dealroom signal
34.4/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
Business model
Manufacturing
Client focus
B2B

Funding history

3 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES COther financing Mar 2021 $120M $480M Mirae Asset Capital · China Merchants Bank · Cormorant Asset Management · ShangBay Capital —
SERIES BOther financing Jun 2019 $74M $296M Sherpa Venture Partners · SDIC Fund Management —
Showing the latest 2 of 3 recorded eventsBook a demo for the full funding history →

Growth signals

EpimAb Biotherapeutics website traffic

Latest recorded traffic for EpimAb Biotherapeutics is 1.8K monthly website visits, up 592.3% over the last three months. EpimAb Biotherapeutics's team declined 5.1% over the past year.

Latest monthly visits1.8K 3-month web change+592.3% 1-year team growth-5.1%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

EpimAb Biotherapeutics in the Pudong ecosystem

Live from Dealroom

The EpimAb Biotherapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

15 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A4 investors entered at this stage

  • Decheng Capital
  • 3E Bioventures
  • Sherpa Venture Partners
  • SDIC Fund Management

Series B and later11 investors entered at this stage

  • CMB International Capital
  • Mirae Asset Capital
  • China Merchants Bank
  • Cormorant Asset Management
  • ShangBay Capital
  • State Development & Investment Corporation (SDIC)
  • Yanchuang Capital
  • Hidragon Capital
  • Hony Capital
  • Octagon Capital Partners
  • Adrian Cheng
Team profiled 7 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 4 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
2 countries with
team presence
🇨🇳 China87.1%
🇺🇸 United States12.9%
2 countries shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about EpimAb Biotherapeutics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See EpimAb Biotherapeutics’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.